Stock AnalizBeOne Medicines (ONC) earnings for the quarter ended September 2026: EPS beats estimates
BeOne Medicines reported results for the quarter ended September 2026 on November 5, 2026. Adjusted earnings per share came in at $3.28 against the analysts’ average forecast of $1.88, a beat of 74.3%.
Revenue for the quarter was $1.89 billion, up 33.8% from $1.41 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 7.7% on the first trading day after the report.
The last four quarters
BeOne Medicines has beaten the analysts’ EPS forecast in 3 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $3.28 | $1.88 | +74.3% | +34% | +7.7% |
| Jun 2026 | $2.05 | $1.63 | +25.7% | +30% | +2.1% |
| Mar 2026 | $1.96 | $0.81 | +143.2% | +35% | +6.6% |
| Dec 2025 | $0.58 | $1.30 | −55.3% | +33% | −10.0% |
What comes next
Analysts expect EPS of $2.63 for the next quarter on average and $9.87 for the fiscal year ending December 31, 2026.
The average analyst price target is $465.00, 12% above the current price of $416.54.
Valuation and score
BeOne Medicines scores 2.0 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 52.8, and its intrinsic value under moderate assumptions is about 85% below the current market value. Full BeOne Medicines analysis with 10 years of financials
Frequently asked questions
What was BeOne Medicines’s EPS for the quarter ended September 2026?
$3.28 adjusted per share, against an analyst consensus of $1.88.
How much revenue did BeOne Medicines report?
$1.89 billion, up 33.8% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.